Evidence map›Paper›PMID 36406860›Full record

ArticleiScience2022

Skewed fate and hematopoiesis of CD34

Benjamin K Estep, Charles J Kuhlmann, Satoru Osuka, Gajendra W Suryavanshi, Yoshiko Nagaoka-Kamata, Ciearria N Samuel, Madison T Blucas, Chloe E Jepson, Paul A Goepfert, Masakazu Kamata

Open access · goldAbstract read
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. COVID-19 Vaccine mRNA Biodistribution: Maternal and Fetal Exposure Risks.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Benjamin K EstepDepartment of Microbiology, University of Alabama at Birmingham, 845 19 Street South, Birmingham, AL 35205, USA.
Charles J KuhlmannDepartment of Microbiology, University of Alabama at Birmingham, 845 19 Street South, Birmingham, AL 35205, USA.
Satoru OsukaDepartment of Neurosurgery, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Gajendra W SuryavanshiDivision of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Yoshiko Nagaoka-KamataDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
Ciearria N SamuelDepartment of Microbiology, University of Alabama at Birmingham, 845 19 Street South, Birmingham, AL 35205, USA.
Madison T BlucasDepartment of Microbiology, University of Alabama at Birmingham, 845 19 Street South, Birmingham, AL 35205, USA.
Chloe E JepsonDepartment of Microbiology, University of Alabama at Birmingham, 845 19 Street South, Birmingham, AL 35205, USA.
Paul A GoepfertDepartment of Medicine and Division of Infectious Diseases, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
Masakazu KamataDepartment of Microbiology, University of Alabama at Birmingham, 845 19 Street South, Birmingham, AL 35205, USA.
University of Alabama at Birmingham · USUniversity of California, Los Angeles · US

Funding

The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5M
Nanodelivery platform for antibody drugs targeting NHLR01CA232015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KAMATA, MASAKAZU · 2018 to 2022
$2.5M
Gene-Engineered Stem Cell Memory T-Cells With Anti-HIV Chimeric Antigen ReceptorsR01AI110200 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KAMATA, MASAKAZU · 2016 to 2019
$1.5M
Eradication of brain/CNS HIV reservoirs via anti-HIV gene-modified macrophagesR21MH130183 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KAMATA, MASAKAZU · 2022 to 2023
$408k
NCI NIH HHS R01 CA232015NIAID NIH HHS R01 AI110200NIAID NIH HHS R01 AI161175NIMH NIH HHS R21 MH130183
6 · The paper itself

Abstract

Umbilical cord blood (UCB) is an irreplaceable source for hematopoietic stem progenitor cells (HSPCs). However, the effects of SARS-CoV-2 infection and COVID-19 vaccination on UCB phenotype, specifically the HSPCs therein, are currently unknown. We thus evaluated any effects of SARS-CoV-2 infection and/or COVID-19 vaccination from the mother on the fate and functionalities of HSPCs in the UCB. The numbers and frequencies of HSPCs in the UCB decreased significantly in donors with previous SARS-CoV-2 infection and more so with COVID-19 vaccination via the induction of apoptosis, likely mediated by IFN-γ-dependent pathways. Two independent hematopoiesis assays, a colony forming unit assay and a mouse humanization assay, revealed skewed hematopoiesis of HSPCs obtained from donors delivered from mothers with SARS-CoV-2 infection history. These results indicate that SARS-CoV-2 infection and COVID-19 vaccination impair the functionalities and survivability of HSPCs in the UCB, which would make unprecedented concerns on the future of HSPC-based therapies.

Indexed as

Developmental biologyHaematologyImmunologyPregnancyStem cells research

Identifiers

PMID36406860
PMCPMC9650991
OpenAlexW4308925515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.